Ann: CEO Interview and Article, page-18

I think they are all relevant simple the scale of the largest pharmaceuticals across the globe wanting a look in highlights the niche of the business and the scale of the potential of what exists within - when the amount of big pharma that have shown interest & inked deals dwarfs anything seen to date from an ASX company i'd keep boasting about that too lol. It does all connect from what I understand the main reason the other deals didn't move further was not that they didn't find anything but that it was deemed too early stage on the discovery front with basically just peptide hits through screens which the company has now taking on board carrying candidates further to look more like something others can just pick up.